Sharing Biosimilar Savings With Physicians Could Boost Market Share Over 50%, Trade Group Says
But even with the legislative and regulatory changes proposed by the Biosimilars Forum, market share would still not reach levels seen in Europe, an analysis by Avalere finds.
You may also be interested in...
Senate Finance Committee staffer explains Republicans are inclined to support more moderate approaches in the near term as the 'bigger ideas' for promoting biosimilars evolve.
Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.
US insurer’s commercial plans will favor the originator drug over biosimilars in return for a price concession from Amgen, while UnitedHealthcare’s Medicare Advantage plans will prefer biosimilars in several categories.